OC's fourth-quarter results reflect a disciplined approach to capital allocation, operational excellence and market expansion.

Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.

Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.

BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.

Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.

Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the fourth quarter of...

Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower...

Solventum's fourth-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.

IONS reports better-than-expected top and bottom-line numbers for the fourth quarter.